This article explores the use of high-dose intravenous vitamin C as an adjunct treatment for cancer patients, showing that it can significantly reduce cancer-related symptoms like pain, fatigue, and nausea, while also improving overall well-being. The therapy is non-toxic, with few mild side effects such as temporary diarrhea and fatigue.
This randomized controlled trial examined the effects of intravenous L-carnitine supplementation on fatigue and exercise capacity in patients with end-stage renal disease (ESRD) undergoing hemodialysis. Patients received L-carnitine at doses of 10 mg/kg, 20 mg/kg, or 40 mg/kg thrice weekly for 24 weeks. While primary analysis showed no significant improvement
This review article examines the role of L-carnitine in cancer cachexia, a syndrome characterized by muscle wasting, fatigue, weight loss, and reduced appetite in cancer patients. L-carnitine supplementation has been associated with improvements in lean body mass, reduced fatigue, and enhanced overall quality of life, although findings across studies remain
The meta-analysis titled “Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis” (Diabet Med, 2004, PMID: 14984445) evaluated the efficacy and safety of intravenous alpha-lipoic acid (600 mg/day) over three weeks in diabetic patients with symptomatic polyneuropathy. Analyzing data from four randomized, double-masked, placebo-controlled trials (n=1,258), the
This systematic review and meta-analysis examined the effects of intravenous α-lipoic acid (ALA) at doses of 300 to 600 mg per day on diabetic peripheral neuropathy (DPN). Analyzing 15 randomized controlled trials, the study found that ALA significantly improved nerve conduction velocities in both motor and sensory nerves, with a
The study titled “The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial” (Diabetes Care, 2003, PMID: 12610036) is a randomized controlled trial investigating the effects of alpha-lipoic acid (ALA) on diabetic polyneuropathy. Involving 120 patients with type 2 diabetes and symptomatic polyneuropathy, participants received either
